VITAE PHARMACEUTICALS, INC (VTAE) financial statements (2021 and earlier)

Company profile

Business Address 502 WEST OFFICE CENTER DR
FORT WASHINGTON, PA 19034
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:77875969808965
Cash and cash equivalents2458121791229
Short-term investments53284852595936
Other undisclosed cash, cash equivalents, and short-term investments(0)00(0)1217(0)
Deferred costs      0
Other undisclosed current assets1122(9)(15)1
Total current assets:79886171717367
Noncurrent Assets
Property, plant and equipment0011000
Long-term investments and receivables    1217 
Long-term investments    1217 
Restricted cash and investments0000000
Deferred costs      0
Total noncurrent assets:111112181
TOTAL ASSETS:79886272849168
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6679866
Accounts payable2233421
Accrued liabilities5445343
Employee-related liabilities   2112
Interest and dividends payable      0
Debt      5
Other undisclosed current liabilities   (2)(1)(1)(2)
Total current liabilities:6678759
Noncurrent Liabilities
Liabilities, other than long-term debt   0000
Deferred revenue and credits   0000
Other undisclosed noncurrent liabilities000    
Total noncurrent liabilities:0000000
Total liabilities:6678769
Stockholders' equity
Stockholders' equity attributable to parent, including:73825464768659
Common stock   0000
Treasury stock, value(0)(0)(0)(0)(0)(0) 
Additional paid in capital267266228227226225189
Accumulated other comprehensive income (loss)00(0)(0)(0)(0)(0)
Accumulated deficit(194)(184)(174)(163)(149)(140)(130)
Other undisclosed stockholders' equity attributable to parent000    
Total stockholders' equity:73825464768659
TOTAL LIABILITIES AND EQUITY:79886272849168

Income statement (P&L) ($ in millions)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Gross profit:0000000
Operating expenses(11)(10)(12)(13)(10)(10)(7)
Operating loss:(11)(10)(12)(13)(10)(9)(7)
Nonoperating income (expense)00000(0)(0)
Investment income, nonoperating0000000
Other nonoperating income  0 0  
Interest and debt expense  0(0) (0)(0)
Net loss:(10)(10)(11)(13)(10)(10)(7)
Other undisclosed net income (loss) attributable to parent  (0)0 00
Net loss available to common stockholders, diluted:(10)(10)(11)(13)(10)(10)(7)

Comprehensive Income ($ in millions)

6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Net loss:(10)(10)(11)(13)(10)(10)(7)
Comprehensive loss:(10)(10)(11)(13)(10)(10)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)0(0)00
Comprehensive loss, net of tax, attributable to parent:(10)(10)(11)(13)(10)(10)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: